RPAM
ADMS

Rhenman & Partners Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-159,924
Closed -$1.37M – 98
2018
Q4 		$1.37M Sell
159,924
-113,669
-42% -$1.48M 0.16% 70
2018
Q3 		$5.48M Sell
273,593
-54,600
-17% -$1.28M 0.55% 61
2018
Q2 		$8.48M Buy
328,193
+118,549
+57% +$3.28M 0.87% 51
2018
Q1 		$5.01M Sell
209,644
-483,269
-70% -$15.2M 0.62% 55
2017
Q4 		$23.5M Sell
692,913
-222,087
-24% -$6.2M 3.17% 3
2017
Q3 		$19.4M Buy
915,000
+546,834
+149% +$10M 2.47% 10
2017
Q2 		$6.44M Buy
368,166
+213,166
+138% +$3.53M 0.92% 39
2017
Q1 		$2.71M Buy
155,000
+25,000
+19% +$426K 0.43% 74
2016
Q4 		$2.2M Hold
130,000
– – 0.42% 69
2016
Q3 		$2.13M Hold
130,000
– – 0.34% 78
2016
Q2 		$1.97M Buy
+130,000
New +$2.14M 0.35% 76

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Rhenman & Partners Asset Management's ADMS Position: Q1 2019 in Review

Rhenman & Partners Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 159,924 shares — an estimated $1.37M sold.

Rhenman & Partners Asset Management first reported a position in ADMS in Q2 2016 and held it in 11 quarters. The position peaked at $23.5M in Q4 2017. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Rhenman & Partners Asset Management reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 159,924 Adamas Pharmaceuticals shares in Q1 2019, an estimated $1.37M.
  • Rhenman & Partners Asset Management first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 11 quarters.
  • Rhenman & Partners Asset Management's Adamas Pharmaceuticals position peaked at $23.5M in Q4 2017.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.